Phase 2 Study clinical trials

Explore recruiting phase 2 study clinical trials.

Recruiting phase 2 study studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Phase 2 Study trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety of a new antiviral and direct therapy on the host

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Antitumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)

Denmark, Italy, France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Denmark, Belgium, Hungary, Germany, France, Spain +3 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications

Czechia, Poland, France, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2 Study trials by city

Phase 2 Study in Toronto Phase 2 Study in Vancouver Phase 2 Study in Montreal Phase 2 Study in Calgary Phase 2 Study in Edmonton Phase 2 Study in Ottawa Phase 2 Study in Winnipeg Phase 2 Study in Quebec City Phase 2 Study in Hamilton Phase 2 Study in Kitchener Phase 2 Study in London Phase 2 Study in Halifax Phase 2 Study in New York Phase 2 Study in Los Angeles Phase 2 Study in Chicago Phase 2 Study in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease